Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28350045 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1TP53HPGDALOX15 | |
| SCHEMBL29367281 | 0.84 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1TP53HPGDALOX15 | |
| SCHEMBL23657933 | 0.78 | PRKACA (0.61) | SMN1; SMN2NPC1TP53HPGDALOX15 | |
| SCHEMBL30765190 | 0.75 | GAA (0.55) | SMN1; SMN2NPC1TP53HPGDRAB9A | |
| SCHEMBL28350195 | 0.74 | RAB9A (0.67) | SMN1; SMN2NPC1RAB9AL3MBTL1GLA | |
| SCHEMBL28354689 | 0.73 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1TP53HPGDALOX15 | |
| SCHEMBL11311373 | 0.73 | NPC1 (0.61) | SMN1; SMN2NPC1TP53HPGDALOX15 | |
| SCHEMBL31306559 | 0.72 | ANO1 (0.72) | ANO1 | |
| SCHEMBL21198649 | 0.72 | ANO1 (0.72) | ANO1 | |
| SCHEMBL12443640 | 0.72 | NPC1 (1.00) | SMN1; SMN2NPC1TP53HPGDALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120202200-A | Oxo-isoindolinyl substituted tetrahydropyrimidinedione-based compounds and applications thereof | 标新生物医药科技(上海)有限公司 | 2025-06-24 | — | — | CN | claimed |
| CN-115160311-B | Difunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2024-03-15 | — | — | CN | claimed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | claimed |
| WO-2023066350-A1 | CRBN E3 LIGASE LIGAND COMPOUND, PROTEIN DEGRADING AGENT DEVELOPED ON THE BASIS OF LIGAND COMPOUND, AND THEIR APPLICATIONS | 标新生物医药科技(上海)有限公司 | 2023-04-27 | — | — | WO | claimed |
| CN-115109055-A | Bifunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2022-09-27 | — | — | CN | claimed |
| CN-115160311-B | Difunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-110753691-B | Compounds for therapeutic and/or prophylactic treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-115109055-B | Difunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023104155-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | 标新生物医药科技(上海)有限公司 | 2023-06-15 | — | — | WO | disclosed |
| CN-115109055-A | Bifunctional compound for EGFR degradation and application thereof | 北京康辰药业股份有限公司 | 2022-09-27 | — | — | CN | disclosed |
| EP-3986565-A1 | NEW EGFR INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2022-04-27 | — | — | EP | disclosed |
| CN-113993589-A | Novel EGFR inhibitors | 豪夫迈·罗氏有限公司 | 2022-01-28 | — | — | CN | disclosed |
| EP-3630754-A1 | COMPOUNDS | H. Hoffnabb-La Roche Ag (CH) | 2020-04-08 | — | — | EP | disclosed |
| CN-109475528-A | Bifunctional molecules for EGFR degradation and methods of use | 达纳-法伯癌症研究所股份有限公司 | 2019-03-15 | — | — | CN | disclosed |
| WO-2018220149-A1 | COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-12-06 | — | — | WO | disclosed |